Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial
| Autor: | Chiara Perella, Michael Rissler, Asta Baranauskaite, Agnieszka Zielińska, Helena Marzo-Ortega, Barbara Schulz, Alejandro Muñoz Jiménez, Effie Pournara, Sanchayita Sadhu, Denis Poddubnyy |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
business.industry spinal pain axial spondyloarthritis interleukin-17A inhibitor tumour necrosis factor inhibitor Phase IIIb Trial Diseases of the musculoskeletal system Placebo Spinal pain Disease activity Rheumatology RC925-935 Internal medicine Medicine Orthopedics and Sports Medicine In patient Secukinumab Axial spondyloarthritis business Original Research |
| Zdroj: | Therapeutic Advances in Musculoskeletal Disease, Vol 13 (2021) Therapeutic Advances in Musculoskeletal Disease |
| ISSN: | 1759-7218 |
| Popis: | Background: This study aimed to evaluate the efficacy and safety of secukinumab 150 mg compared with placebo in the management of spinal pain and disease activity in patients with axial spondyloarthritis (axSpA) at Week 8 and up to Week 24. Methods: Patients ( n = 380) with active axSpA were randomized (3:1) to secukinumab 150 mg (Group A) or placebo (Group B). At Week 8, patients from Group A with an average spinal pain score Results: At Week 8, the odds of achieving an average spinal pain score of Conclusion: Secukinumab provided rapid and significant improvement in spinal pain at Week 8 which was sustained or increased further up to Week 24 in patients with axSpA. Trial Registration: ClinicalTrials.gov: NCT03136861. Registered May 2, 2017. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|